Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis

Summary

Will Abatacept reduce priming of the hair follicle specific T cells and thereby reduce hair follicle associated infiltration and improve hair growth. This is a double blind placebo controlled study to test the safety and efficacy of Abatacept in the treatment of 64 subjects diagnosed with alopecia totalis or alopecia universalis. Subjects will be randomized 1:1 to the placebo or treatment arm and will receive 6 months of treatment with the study medication or placebo, followed by a 6 month observational period.

Timeline

Start

2011-09

Primary completion

2012-06

Completion

2012-06

Drugs

Indications